Market Place
Sourcing Support
ALX Oncology Evorpacept Combo Shows Activity In Breast Cancer
10 Dec 2024 //
GLOBENEWSWIRE
ALX Oncology to Participate in Piper Sandler 36th Annual Conference
26 Nov 2024 //
GLOBENEWSWIRE
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
14 Nov 2024 //
GLOBENEWSWIRE
ALX Oncology Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
ALX Oncology Announces November Investor Conference Participation
04 Nov 2024 //
GLOBENEWSWIRE
ALX Oncology`s Ph 1b/2 Evorpacept+Zanidatamab Results at SABCS
01 Nov 2024 //
GLOBENEWSWIRE
ALX Oncology To Present At Cantor Fitzgerald Conference
09 Sep 2024 //
GLOBENEWSWIRE
ALX Oncology Doses First Patients In UMBRELLA Study
04 Sep 2024 //
GLOBENEWSWIRE
ALX Oncology Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
06 Aug 2024 //
GLOBENEWSWIRE
ALX`s fizzling CD47 response rate sends stock spiraling down
01 Aug 2024 //
FIERCE BIOTECH
ALX Oncology To Host Call On ASPEN-06 Phase 2 Evorpacept Data
31 Jul 2024 //
GLOBENEWSWIRE
ALX Oncology Reports ASPEN-06 Phase 2 Data In Gastric Cancer
31 Jul 2024 //
GLOBENEWSWIRE
ALX Oncology`s Evorpacept ADC Combo Data In Advanced Bladder Cancer
02 Jun 2024 //
GLOBENEWSWIRE
ALX Oncology At Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
ALX Oncology Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
ALX Oncology Appoints Allison Dillon as Chief Business Officer
07 May 2024 //
GLOBENEWSWIRE
ALX Oncology Initiates Neoadjuvant Trial In Oropharyngeal Cancer
30 Apr 2024 //
GLOBENEWSWIRE
ALX Oncology`s Evorpacept Abstracts at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
ALX Oncology Reports Encouraging Data of Evorpacept for Non-Hodgkin Lymphoma
09 Apr 2024 //
GLOBENEWSWIRE
ALX Oncology Has `Elevated Valuation` - Analyst Downgrades Stock
09 Mar 2024 //
YAHOO FINANCE
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
ALX Oncology Announces Evorpacept Clinical Abstracts Accepted for Presentation
05 Mar 2024 //
GLOBENEWSWIRE
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
ALX Oncology Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
ALX Oncology Announces November Investor Conference Participation
01 Nov 2023 //
GLOBENEWSWIRE
ALX Oncology Announces Closing of Public Offering
10 Oct 2023 //
GLOBENEWSWIRE
ALX Oncology Announces Pricing of Public Offering
05 Oct 2023 //
GLOBENEWSWIRE
ALX Oncology Announces Proposed Public Offering
04 Oct 2023 //
GLOBENEWSWIRE
Why ALX Oncology Stock Is Skyrocketing Today
03 Oct 2023 //
FOOL
ALX Oncology Reports Positive Phase 2 Clinical Trial Results of Evorpacept
03 Oct 2023 //
GLOBENEWSWIRE
ALX Oncology to Host Investor Call and Webcast on October 3, 2023
02 Oct 2023 //
GLOBENEWSWIRE
ALX Oncology Realigns Executive Leadership Team
06 Sep 2023 //
GLOBENEWSWIRE
ALX Oncology Announces September Investor Conference Participation
31 Aug 2023 //
GLOBENEWSWIRE
ALX follows Gilead in axing cancer trials as data disappoint
12 Aug 2023 //
FIERCE BIOTECH
ALX Oncology Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
ALX Oncology Receives Orphan Drug Designation from the EC for Evorpacept
26 Jun 2023 //
GLOBENEWSWIRE
ALX Oncology Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
ALX Oncology doses first patient in trial of evorpacept for ovarian cancer
10 May 2023 //
CLINICAL TRIALS ARENA
ALX Oncology Announces 1st Patient Dosed in Ph2 Investigator Trial of Evorpacept
09 May 2023 //
GLOBENEWSWIRE
ALX Oncology Announces Trial Collaboration with Sanofi to Evaluate Evorpacep
25 Apr 2023 //
GLOBENEWSWIRE
ALX Oncology and Quantum Collaborative Announce Patient Dosed in I-SPY-P1 TRIAL
13 Mar 2023 //
GLOBENEWSWIRE
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
ALX Oncology Announces First Patient Dosed in ASPEN-07, PI Study of Evorpacept
16 Feb 2023 //
GLOBENEWSWIRE
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
05 Jan 2023 //
GLOBENEWSWIRE
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
ALX Oncology reports complete response with anti-CD47 candidate in combo trial
12 Dec 2022 //
ENDPTS
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept
12 Dec 2022 //
GLOBENEWSWIRE
ALX Oncology Appoints Scott Garland to its Board of Directors
29 Nov 2022 //
GLOBENEWSWIRE
ALX Oncology Reports3Q 2022 Financial Results and Provides Clinical DevP
08 Nov 2022 //
GLOBENEWSWIRE
ALX Oncology to Present New Clinical Data on Evorpacept Acute Myeloid Leukemia
03 Nov 2022 //
GLOBENEWSWIRE
ALX Oncology Announces Upcoming Investor Conference Participation
02 Nov 2022 //
GLOBENEWSWIRE
Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole
01 Nov 2022 //
ENDPTS
ALX Enters $100M Loan Agreement with Oxford Finance & Silicon Valley Bank
31 Oct 2022 //
GLOBENEWSWIRE
ALX Oncology Announces Trials in Progress Abstracts Accepted
05 Oct 2022 //
GLOBENEWSWIRE
ALX Oncology to Participate in the Cantor Oncology, Hematology
21 Sep 2022 //
GLOBENEWSWIRE
ALX Oncology Announces Upcoming Investor Conference Participation
01 Sep 2022 //
GLOBENEWSWIRE
ALX & Quantum Leap Collaborative Announce the Selection of Evorpacept
15 Aug 2022 //
GLOBENEWSWIRE
ALX starts Phase II trial of colorectal cancer combo therapy
12 Aug 2022 //
CLINICALTRIALSARENA
ALX Oncology Announces First Patient Dosed in Ph2 InG Trial of Evorpacept
11 Aug 2022 //
GLOBENEWSWIRE
